News | January 25, 2009

Edwards Lifesciences Launches New Mitral Valve Repair Ring

January 26, 2009 - Edwards Lifesciences Corp. today launched the Carpentier-Edwards Physio II mitral valve repair ring at the 45th annual meeting of the Society of Thoracic Surgeons (STS) in San Francisco.

The new therapy represents the next generation of the Carpentier-Edwards Physio ring heart valve repair device.

"Since the creation of the original Carpentier-Edwards Physio ring, scientific knowledge about mitral valve anatomy and pathology has expanded significantly, and these new learnings have been applied in the design of the new Carpentier-Edwards Physio II ring," said Alain F. Carpentier, M.D., Ph.D., professor and chairman emeritus of cardiovascular surgery at the Hôpital Europeen Georges Pompidou in Paris, and the inventor of the original Carpentier-Edwards Physio ring. Carpentier, the foremost pioneer in the field of heart valve repair for more than 40 years, and David H. Adams, M.D., one of the leading mitral repair authorities in the world, are the co-inventors of the next-generation ring.

The Carpentier-Edwards Physio II ring is a mitral valve repair solution. It is the only annuloplasty ring offering "shape optimization," which matches the geometry of the ring to the characteristics of the patient’s diseased mitral valve, and does not limit repair options based on etiology, or cause, of the mitral valve disease. Several new features, such as a unique sewing cuff, provide surgeons with a device that is also easier to implant.

"The Carpentier-Edwards Physio II ring represents a paradigm shift in our thinking about ring geometry and I believe it is going to result in a higher quality of valve repair in the majority of patients suffering from mitral valve disease," said Adams, the Marie-Josée and Henry R. Kravis Professor and chairman of the department of cardiothoracic surgery at Mount Sinai Medical Center. Adams and Carpentier are advisers to and receive royalty payments from Edwards Lifesciences.

Edwards received 510(k) clearance from the FDA to market the Carpentier-Edwards Physio II ring. It will also be available in Europe, as the company has also received CE Mark approval for European sales of the device.

For more information:

Related Content

SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts
Technology | Cardiovascular Surgery | February 01, 2019
Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) for a design...
Transplanting Pig Hearts Into Humans One Step Closer. A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

A pig heart, shown here, is very similar in size and anatomy to a human heart. For this reason, pigs are used extensively in pre-clinical animal testing for new implantable cardiovascular devices. If pig hearts could be used for human transplantation, it would greatly alleviate shortages of donor human hearts.

News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Overlay Init